Expression of aquaporin 5 in primary carcinoma and lymph node metastatic carcinoma of non‑small cell lung cancer by Yang, HONG et al.
Title Expression of aquaporin 5 in primary carcinoma and lymph nodemetastatic carcinoma of non-small cell lung cancer
Author(s) Song, TIANHE; Yang, HONG; Ho, JCM; Tang, SCW; Sze, CWS;Lao, L; Wang, Y; Zhang, Y
Citation Oncology Letters, 2015, v. 9, p. 2799-2804
Issued Date 2015
URL http://hdl.handle.net/10722/211836
Rights This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
ONCOLOGY LETTERS  9:  2799-2804,  2015
Abstract. Aquaporin 5 (AQP5), a water channel protein, is 
highly expressed in non-small cell lung cancer (NSCLC) tissues 
compared with adjacent normal tissues. AQP5 expression in lung 
cancer tissues is associated with a poor prognosis. The present 
study aimed to analyze the expression of AQP5 and investi-
gate its role in primary and lymph node metastatic NSCLCs. 
An immunohistochemical labeled streptavidin-biotin method 
was used to determine the expression of AQP5 in 94 cases of 
NSCLC primary carcinoma, which included 51 cases accom-
panied by lymph node metastasis. The results revealed that 
the expression of AQP5 was significantly higher in adenocar-
cinomas compared with squamous cell carcinomas (P=0.002). 
In addition, the percentage of AQP5 expression in the primary 
carcinomas with lymph node metastasis was significantly higher 
compared with those without lymph node metastasis (P=0.024). 
However, no statistically significant difference in the percentage 
of AQP5 expression was observed between the metastatic and 
the primary carcinomas (P=0.377). The expression of AQP5 
exhibited a correlation with the tumor-node-metastasis staging 
of NSCLC (P=0.027). The percentage of AQP5 expression in 
stage III and IV tumors was higher than that in stage I and II 
tumors. In addition, AQP5 expression was correlated with the 
survival rate of NSCLC patients (P=0.051). In conclusion, the 
results of the present study provide evidence for the AQP5-facil-
itated incidence, progression and metastasis of NSCLC. 
Therefore, AQP5 may be used as a potential target to investigate 
the incidence, progression and metastasis of NSCLC.
Introduction
Lung cancer is the leading cause of cancer-associated mortali-
ties in males and females worldwide (1,2). The two primary 
types of lung cancer, small cell lung cancer and non-small cell 
lung cancer (NSCLC), account for 90% of all the diagnosed 
lung cases. NSCLC, which includes squamous cell carcinoma, 
adenocarcinoma and large cell carcinoma, constitutes ~80% 
of all lung cancer types (3-5). The incidence, progression 
and underlying mechanisms of tumor metastasis have been a 
focus of investigation. Although advances have been made in 
the treatment and diagnosis of NSCLC over the last several 
years, the overall prognoses for patients with NSCLC remain 
poor (6). A number of studies have attempted to identify novel 
prognostic and predictive biomarkers for the diagnosis and 
treatment of NSCLC (7,8).
Previous studies have established that tumor growth, 
development, invasion and metastasis depend upon sufficient 
nutrient supply and metabolism, and that water molecules are 
important in the modulation of the tumor microenvironment 
and metabolism (9,10). Increasing evidence has demonstrated 
that aquaporins (AQPs), a family of small transmembrane 
proteins responsible for water transport, are involved in the 
incidence and progression of cancer (11-13). In particular, 
AQP1 has been found to be implicated in the incidence and 
progression of tumors (11,12), whilst AQP5 has been proposed 
to enhance tumor growth and be associated with tumor metas-
tasis (13). 
AQPs are widely distributed in a variety of organs, and 
primarily regulate the transport of water molecules by osmotic 
pressure. In addition, AQPs regulate the transmembrane 
transport of other small molecules, including glycerol and 
urea. In total, 12 types of AQPs are expressed in humans, 
and AQP1, 3, 4 and 5 are expressed in the respiratory system. 
AQP5 is primarily distributed in the epithelial cells of type I 
alveoli and glandular epithelial cells of the submucosal glands. 
Its main functions are water transport and involvement in 
glandular secretion and airway hyperactivity (14). Previous 
studies have established that AQP1, 3 and 5 are associated 
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with malignant tumors. Furthermore, it has been demonstrated 
that AQP1 and 3 promote the metastasis of tumors (15,16). 
Woo et al (13) revealed that AQP5 enhanced the proliferation 
of tumor cells. In addition, high AQP5 expression has been 
identified to be associated with the metastasis of rectal, uterine 
and ovarian cancer (17-19).
However, only a limited number of studies have investi-
gated the role of AQP5 in cancer. The aims of the present study 
were to investigate the expression of AQP5 and determine its 
role in NSCLC.
Patients and methods
Study participants. In total, 145 patients were selected by 
Professor Ying Wang from the Sichuan Cancer Hospital 
(Chengdu, China) between August 2006 and February 2008. 
The patients were recruited through oncologist referrals, 
having been diagnosed with NSCLC following presentation 
with lung cancer symptoms, such as chest pain, shortness of 
breath, hemoptysis and wheezing. The inclusion criteria were 
as follows: Patients with NSCLC; patients treated with surgery; 
and patients agreed to participate the present study. All the 
patients provided written informed consent for participation. 
The study experiments conformed to the ethical guidelines of 
the 1975 Declaration of Helsinki (20), and were approved by 
the Institutional Review Board of the Sichuan Cancer Hospital.
Of the 145 NSCLC patients, 51 patients were excluded due 
to having received prior radiation therapy or chemotherapy, 
having incomplete clinical information, or unavailability of 
paraffin‑embedded tissue sections. The remaining 94 patients 
with primary NSCLC (male, 68; female, 26; age range, 
29-82 years) were included in the present study (Fig. 1). These 
patients had not received prior radiation therapy or chemo-
therapy. Complete clinical information and paraffin‑embedded 
sections were obtained. The pathological staging of the 
histological types was based on the standard histological 
classification of lung cancer, established by the World Health 
Organization in 2004 (21). Following the collection of clinical 
samples for the present study, the presence or absence of 
metastasis was assessed.
Patient follow‑up. The patients were routinely followed-up 
on an outpatient basis, according to a standard protocol. 
Briefly, in the first year following treatment/surgery, visits 
were conducted every 3 months; in the second and third years, 
every 6 months; and until the end of the fifth year, once every 
12 months. Patients who did not attend the outpatient program 
were contacted by telephone and/or letter in order to obtain 
follow-up data, until the visit cut-off date on August 30, 2012. 
The rate of missed visits was 4.6%. The period of survival 
was calculated from the date of diagnosis to the date of the 
final follow‑up or the date of mortality due to recurrence or 
metastasis.
Immunohistochemical staining. AQP5 expression in the 
biopsy tissue specimens was detected by immunohistochem-
ical analysis. The biopsy tissue specimens were collected from 
the NSCLC patients who had undergone surgical removal 
of the tumor. Tumor sections measuring 5 µm in thickness 
were initially deparaffinized and rehydrated in a graded 
series of alcohols: Slides were submerged in xylene two 
times for 5 min, before soaking in 100% ethanol two times 
for 5 min, 95% ethanol for 5 min and in 80% ethanol for 
5 min. Following rehydration, an antigen retrieval process was 
performed under high pressure (22). The sections were then 
washed twice in phosphate-buffered saline (PBS)-Tween 20 
for 2 min each. The sections were allowed to cool prior to 
blocking with 20% goat serum in PBS for 15 min. Next, the 
sections were incubated at 37˚C for 1 h, and then overnight 
at 4˚C with a polyclonal rabbit antibody against AQP5 (dilu-
tion, 1:100; Santa Cruz Biotechnology, Inc., Dallas, TX, 
USA; catalog no. SC-28628). Subsequent to washing three 
times with PBS-Tween 20 for 2 min each, the sections were 
incubated for 10 min at room temperature in a peroxidase 
blocking solution. Next, the sections were rinsed three times 
with PBS-Tween 20 for 2 min each and incubated with a 
biotinylated goat anti-rabbit IgG secondary antibody (dilution, 
1:100; Santa Cruz Biotechnology, Inc.; catalog no. SC-2040) 
in PBS. Subsequent to washing, the sections were incubated in 
a horseradish peroxidase-streptavidin solution (dilution, 1:100; 
Sigma-Aldrich, St. Louis, MO, USA) for 30 min at 37˚C. The 
sections were again rinsed three times in PBS-Tween 20 for 
2 min each and incubated in a peroxidase substrate solu-
tion (Sigma-Aldrich). Subsequently, the sections were rinsed 
in running tap water for 2-5 min, followed by dehydration 
with 95% ethanol for 1 min and twice with 100% ethanol for 
3 min each. The sections were then cleared twice in 100% 
xylene for 5 min each and then covered with neutral gum 
(Bioworld Technology, Inc., St. Louis Park, MN, USA). The 
primary and secondary antibodies and 3,3'diaminobenzidine 
tetrahydrochloride (DAB) were obtained from Santa Cruz 
Biotechnology, Inc. All the steps were treated with deoxyri-
bonuclease (Life Technologies, Grand lsland, NY, USA). This 
method was used to detect the expression of AQP5 in the lung 
cancer tissues. Microscopic immunohistochemical analysis 
of the tissue sections was performed using an Olympus BX41 
microscope (Olympus Corporation, Tokyo, Japan).
Scoring of immunohistochemical staining results. Scoring 
of the AQP5 expression levels and analysis of all the speci-
mens were performed by technicians who were blinded to 
the clinical information. The appearance of yellowish-brown 
granules in the cytoplasm was regarded to be a positive result 
for the expression of AQP5. The staining intensity of the 
AQP5-positive cells was scored based on the percentage of 
stained tumor cells as follows: i) 0, unstained; ii) 1, pale yellow 
staining; iii) 2, yellowish-brown staining; and iv) 3, brown 
staining. Scores were also assigned according to the percentage 
of AQP5-positive cells as follows: i) 4, >75%; ii) 3, 51-75%; 
iii) 2, 11-50%; iv) 1, ≤10%; and v) 0, negative. The two scores 
obtained for each case were then multiplied and assigned to one 
of the following groups: i) 0-2, (-); ii) 3-5, (+); iii) 5-8, (++); and 
iv) 9-12, (+++) (23).
Statistical analysis. To avoid bias, sample collection and data 
analysis were conducted without knowledge of the subject 
status. SPSS version 15.0 statistical software (SPSS, Inc., 
Chicago, IL, USA) was used for data analysis. The χ2 test 
was used to compare differences in AQP5 expression, the 
Kaplan-Meier method was used for the analysis of the survival 
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data and the log-rank test was used to compare the survival 
curves. P<0.05 was considered to indicate a statistically 
significant difference.
Results
Study population and baseline data. Fig. 1 shows the screening, 
randomization and participant flow of the different groups. Of 
the 145 randomly selected patients, 94 were found to conform 
to the selection criteria. Of the 94 cases of NSCLC (male, 68; 
female, 26; mean age, 58.68 years; age range, 29-82 years), 
28 presented with squamous cell carcinoma, 16 with adeno-
squamous carcinoma and 50 with adenocarcinoma (Table I). 
Overall, there were 15 cases of highly-differentiated carci-
noma, 33 cases of moderately-differentiated carcinoma, 
Figure 1. Study population. Flowchart revealing the composition of the patient collective included in the present study. NSCLC, non-small cell lung cancer.
Table I. Clinicopathological characteristics of NSCLC 
patients (n=94).
Clinicopathological characteristics n (%)
Gender 
  Male 68 (72.3)
  Female 26 (27.7)
Histological type 
  Squamous cell carcinoma 28 (29.8)
  Adenocarcinoma 50 (53.2)
  Adenosquamous carcinoma 16 (17.0)
Differentiationa 
  Well 15 (16.0)
  Moderate 33 (35.1)
  Poor 30 (31.9)
TNM staging 
  I 15 (16.0)
  II 33 (35.1)
  III 36 (38.3)
  IV 10 (10.6) 
a16 cases could not be staged. NSCLC, non-small cell lung cancer; 
TNM, tumor-node-metastasis.
 Figure 2. Aquaporin 5 expression in (A) adenocarcinoma and (B) lymph node 
metastasis (labeled streptavidin biotin staining; magnification, x200). 
  A
  B
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30 cases of poorly-differentiated carcinoma and 16 cases 
of adenosquamous carcinoma that could not be staged. In 
addition, 51 cases of primary carcinoma were accompanied 
by metastasis, including 39 cases with lymph node‑specific 
metastasis (requirement for metastasis, ≥5x high-power 
visual field). In accordance with the revised standard for 
the 2009 lung cancer international tumor-node-metastasis 
(TNM) staging (24), 15 cases were at stage I, 33 cases were 
at stage II, 36 cases were at stage III and 10 cases were at 
stage IV (Table I). Patients with stages III and IV NSCLC did 
not undergo surgical treatment.
Association between AQP5 expression percentage and the 
clinical pathological features of NSCLC. AQP5 expression 
was associated with the histological type and TNM staging 
of the NSCLCs. The percentage of AQP5 expression in the 
adenocarcinomas was significantly higher compared with 
that in the squamous carcinomas (P=0.002). Of the 16 cases 
of adenosquamous carcinoma, 11 were positive for the 
Figure 3. Survival curves of non-small cell lung cancer patients with different 
expression levels of AQP5. AQP5, aquaporin 5. 
Table III. AQP5 expression in primary and metastatic carcinomas.
 AQP5 expression
 --------------------------------------------------------------------------------------
Groups n - + ++ +++ χ2 P-value
Lymph node metastasis
  No 43 25 6   9   3 9.40 0.024
  Yes 51 17 8 11 15  
Tumor type
  Primary carcinoma 39 16 7   5 11 3.09 0.377
  Metastatic carcinoma 39 11 5 10 13
AQP5, aquaporin 5.
 
Table II. AQP5 expression in different pathological tissues.
 AQP5 expression
 -------------------------------------------------------------------------------
Pathological features n - + ++ +++ χ2 P-value
Histological type       
  Squamous cell carcinoma 28 20 5   2   1 14.38 0.002
  Adenocarcinoma 50 16 8 14 12  
  Adenosquamous carcinoma 16   4 3   6   3 
Differentiationa
  Well 15   8 3   2   2 2.16 0.904
  Moderate 33 16 6   6   5  
  Poor 30 12 4   8   6  
TNM staging
  I 15 11 1   2   1 18.73 0.027
  II 33 14 5   9   5  
  III 36 16 5   4 11  
  IV 10   1 3   5   1  
a16 cases could not be staged. AQP5, aquaporin 5; TNM, tumor-node-metastasis.
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expression of AQP5, which yielded an expression percentage 
of 68.8%. This was significantly higher than the 31.2% 
expression percentage (5 cases) of the squamous carcinoma 
group (P<0.034). The positive expression percentages of 
AQP5 in stages III and IV NSCLCs were significantly higher 
compared with those in stages I and II NSCLCs (P=0.027). 
The expression percentages of AQP5 in the highly-, 
moderately- and poorly-differentiated tumors were 46.7, 
51.5 and 60.0%, respectively, and no statistically significant 
differences were observed (P=0.904; Table II).
Association between AQP5 expression and NSCLC 
metastasis. The AQP5 expression percentages in primary 
carcinomas accompanied by lymph node metastasis were 
significantly higher compared with those in primary carci-
nomas not accompanied by lymph node metastasis (P=0.024). 
The AQP5 expression percentages in metastatic carcinoma 
cases did not exhibit a statistically significant difference 
compared with the primary carcinoma cases (P=0.377; 
Table III). In primary carcinoma cases with high AQP5 
expression, the metastatic carcinomas exhibited augmented 
AQP5 expression. Therefore, AQP5 may be involved in the 
metastasis of NSCLC. In addition, the results indicated that 
NSCLCs with elevated AQP5 expression are more likely to 
be associated with lymph node metastasis.
Association between AQP5 expression and survival rate of 
NSCLC patients. AQP5 expression was evaluated in tissue 
samples by immunohistochemical analysis. The appearance 
of yellowish-brown granules in the cytoplasm was regarded 
as a positive result for the expression of AQP5 (Fig. 2). The 
staining intensity of the AQP5-positive cells was scored, as 
well as the percentage of AQP5-positive cells. The two scores 
obtained for each case were multiplied and assigned to one of 
the following groups: (-), (+), (++), and (+++). The results of 
the present study revealed that the five‑year survival rate of 
NSCLC patients with scores of (-), (+), (++), and (+++) were 
21.43, 28.57, 10.00 and 11.11%, respectively. The log-rank 
test demonstrated a clear association between the expression 
of AQP5 and the survival rate of NSCLC patients (P=0.051; 
Fig. 3). An upregulation in the expression of AQP5 was corre-
lated with a decrease in the survival rate of NSCLC patients.
Discussion
The present study examined the expression of AQP5 in 
94 cases of NSCLC primary carcinoma and 51 cases of 
metastatic carcinoma. The results revealed that AQP5 
expression in NSCLCs was associated with lymph mode 
metastasis. AQP5 expression in NSCLC primary carcinomas 
accompanied by lymph node metastasis was markedly higher 
compared with those without lymph node metastasis. When 
the AQP5 expression levels in primary carcinomas was 
compared with that in metastatic carcinomas, no statistically 
significant difference was identified. In cases of primary 
carcinoma with high AQP5 expression, the metastatic carci-
nomas also exhibited augmented AQP5 expression. This 
indicated that NSCLCs with elevated AQP5 expression levels 
are more likely to be associated with lymph node metastasis, 
and that AQP5 plays an important role in the metastasis of 
NSCLCs. In addition, the present study revealed that AQP5 
expression was associated with the NSCLC clinical stage. 
The expression levels of AQP5 in stage III and IV tumors 
were significantly higher compared with stage I and II 
tumors. This observation indicated that a high level of AQP5 
was associated with the promotion of lung cancer metastasis. 
Furthermore, AQP5 was revealed to be closely associated 
with the incidence and progression of adenocarcinomas. The 
positive expression percentage of AQP5 in adenocarcinomas 
was 68.0%, which was markedly higher than the value of 
28.6% in squamous carcinomas. In the 16 cases of squamous 
carcinoma, the positive expression percentage of AQP5 in 
adenocarcinomas was 68.8%, which was notably higher than 
the value of 31.2% in squamous carcinomas. These results 
indicate an association between AQP5 and adenocarcinomas 
and a role for AQP5 in the incidence and progression of 
adenocarcinomas. Whether the elevated expression levels of 
AQP5 in adenocarcinomas can be used as an indirect marker 
during clinical and pathological diagnosis requires further 
investigation. In addition, the mechanisms involved in the 
promotion of tumor metastasis are under investigation. AQP5 
phosphorylation has been demonstrated to be an important 
event involved in the promotion, incidence and progression 
of tumors (13). Previous studies have established that AQP5 
can activate the RAS/ERK/RB pathway in rectal cancer 
cells and enhance the incidence and progression of cancer. 
Furthermore, an association with the metastasis of rectal 
cancer was also identified (17,25).
In conclusion, the present study revealed an association 
between high AQP5 expression and the high invasiveness 
and metastatic percentage of NSCLC, as well as with the 
incidence and progression of adenocarcinomas. Histopatho-
logical analysis revealed an association between AQP5 and 
the metastasis, incidence and progression of NSCLC.
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